PMID- 37062975
OWN - NLM
STAT- MEDLINE
DCOM- 20230418
LR  - 20230720
IS  - 1469-0756 (Electronic)
IS  - 0032-5473 (Linking)
VI  - 98
IP  - 1163
DP  - 2022 Sep 1
TI  - Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as 
      adjuvant treatment for HER2 positive breast cancer: a pilot study.
PG  - 666-669
LID - 10.1136/postgradmedj-2021-140319 [doi]
AB  - BACKGROUND: Subcutaneous (SC) trastuzumab is similar to intravenous trastuzumab 
      in terms of pharmacokinetics, efficacy and tolerability. The use of dual 
      anti-HER2 agents trastuzumab and pertuzumab has become the new standard for 
      node-positive HER2-positive breast cancers at adjuvant setting, but the safety 
      and tolerability of combining SC trastuzumab and intravenous pertuzumab is not 
      well studied. METHODS: This was a prospective single-arm pilot study with locally 
      advanced HER2-positive breast cancer who received adjuvant SC trastuzumab and 
      intravenous pertuzumab after standard anti-HER2 treatment with chemotherapy. 
      Primary outcomes included adverse events (AEs), severe AEs and cardiac AEs. 
      Secondary outcome was invasive disease-free survival (iDFS). RESULTS: With a 
      median follow-up of 21.7 months, 20 patients were enrolled. One patient (5%) 
      developed asymptomatic drop in left ventricular ejection fraction from 69% to 
      53%. Two patients (10%) developed grade 1 injection site reaction related to SC 
      trastuzumab. There were no grade 2 or above AEs. All AEs were transient. No new 
      AEs were observed. The 1-year iDFS was 90% (95% CI 0.656 to 0.974). CONCLUSIONS: 
      Combination of SC trastuzumab and intravenous pertuzumab for HER2-positive breast 
      cancer is a safe and well-tolerated option in adjuvant setting.
CI  - (c) Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Wong, Chi Yan
AU  - Wong CY
AUID- ORCID: 0000-0003-1362-2442
AD  - Medicine, Queen Mary Hospital, Hong Kong, Hong Kong.
FAU - Leung, Roland
AU  - Leung R
AD  - Medicine, University of Hong Kong, Hong Kong, Hong Kong.
FAU - Kwok, Gin Wai
AU  - Kwok GW
AD  - Medicine, Queen Mary Hospital, Hong Kong, Hong Kong.
FAU - Tsang, Josephine
AU  - Tsang J
AD  - Medicine, Queen Mary Hospital, Hong Kong, Hong Kong.
FAU - Li, Bryan
AU  - Li B
AD  - Medicine, Queen Mary Hospital, Hong Kong, Hong Kong.
FAU - Yau, Thomas
AU  - Yau T
AD  - Medicine, University of Hong Kong, Hong Kong, Hong Kong.
FAU - Chiu, Joanne
AU  - Chiu J
AUID- ORCID: 0000-0002-8320-3166
AD  - Medicine, University of Hong Kong, Hong Kong, Hong Kong.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Postgrad Med J
JT  - Postgraduate medical journal
JID - 0234135
RN  - P188ANX8CK (Trastuzumab)
RN  - K16AIQ8CTM (pertuzumab)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Humans
MH  - Female
MH  - Trastuzumab/adverse effects
MH  - *Breast Neoplasms/drug therapy
MH  - Pilot Projects
MH  - Stroke Volume
MH  - Prospective Studies
MH  - Receptor, ErbB-2/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - breast tumours
EDAT- 2023/04/18 06:00
MHDA- 2023/04/18 10:16
CRDT- 2023/04/17 02:52
PHST- 2021/04/20 00:00 [received]
PHST- 2021/05/17 00:00 [accepted]
PHST- 2023/04/18 10:16 [medline]
PHST- 2023/04/17 02:52 [entrez]
PHST- 2023/04/18 06:00 [pubmed]
AID - 7097025 [pii]
AID - 10.1136/postgradmedj-2021-140319 [doi]
PST - ppublish
SO  - Postgrad Med J. 2022 Sep 1;98(1163):666-669. doi: 
      10.1136/postgradmedj-2021-140319.